FindTrial
Sign In

Fat and iron content in prostate cancer and prostatic hyperplasia based on multiparametric magnetic resonance

Precision prediction of time to development of CRPC and clinical utility based on mpMRI imaging

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100046948
Enrollment
Unknown
Registered
2021-05-31
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

prostatic hyperplasia group and the prostate cancer group:Nil

Sponsors

The First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Prostate magnetic resonance imaging (MRI), including conventional T2WI, DWI, and multiecho T2 , was performed in our hospital from July 2021 to September 2021; 2. The interval between prostate surgery and MRI at our institution was less than 6 weeks; 3. No diseases affecting lipid and iron metabolism disorders, except prostate cancer.

Exclusion criteria

Exclusion criteria: 1. Previous PCA treatment, including focus treatment (cryotherapy), surgery, hormone or radiation therapy; 2. Suffer from diseases that affect lipid metabolism and iron metabolism except prostate cancer; 3. T2 and traditional T2W imaging artifacts make the inspection non-diagnostic.

Countries

China

Contacts

Public ContactHuang Yuhua

the First Affiliated Hospital of Soochow University

sdfyy_hyh@163.com+86 18913752992

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026